Anavex Life Sciences Corp

(NASDAQ:AVXL)

Latest On Anavex Life Sciences Corp (AVXL):

Date/Time Type Description Signal Details
2023-05-09 09:59 ESTNewsAnavex Life Sciences GAAP EPS of -$0.17 beats by $0.01N/A
2023-05-09 09:59 ESTNewsAnavex Life Sciences Corp. (AVXL) Q2 2023 Earnings Call TranscriptN/A
2023-05-08 21:26 ESTNewsAnavex Life Sciences Q2 2023 Earnings PreviewN/A
2023-05-04 09:38 ESTNewsAnavex And The Antioxidant Treatment Of Alzheimer's DiseaseN/A
2023-04-06 10:52 ESTNewsBiogen And Eisai, Cassava Sciences, And Anavex: Clinical Trial Results In Need Of RevisionsN/A
2023-03-31 01:41 ESTNewsAnavex gains on long-term data for Parkinson’s disease therapyN/A
2023-03-16 14:51 ESTNewsBuy Anavex For Its Likely Positive Alzheimer's Disease DataN/A
2023-03-08 22:50 ESTNewsAnavex: Many Questions Answered, A Few Still Left, But Things Are Progressing WellN/A
2023-02-09 22:02 ESTNewsAnavex Life Sciences: Recent Earnings Reveals Strong Cash Position To Get ANAVEX 2-73 Through FDAN/A
2023-02-07 16:44 ESTNewsAnavex Life Sciences GAAP EPS of -$0.17 beats by $0.02N/A
2023-02-07 16:44 ESTNewsAnavex Life Sciences Corp. (AVXL) Q1 2023 Earnings Call TranscriptN/A
2023-02-07 16:43 ESTNewsAnavex hits two-month high after Q1 FY23 resultsN/A
2023-02-06 15:12 ESTNewsAnavex Life Sciences Q1 2023 Earnings PreviewN/A
2023-02-02 15:43 ESTNewsAnavex gains as trial for Rett syndrome candidate exceeds enrollment targetN/A
2023-01-31 00:23 ESTNewsApproval For Anavex's Blarcamesine Looks Inevitable After Biogen's Leqembi ApprovedN/A
2023-01-17 17:52 ESTNewsAnavex: Drug Treatments For Early Alzheimer's DiseaseN/A
2023-01-12 19:56 ESTNewsAnavex: Despite Positive Spin, No Clarity On AnomaliesN/A
2023-01-06 22:58 ESTNewsLilly, Anavex, other Alzheimer's drug developers rise modestly on Biogen lecanemab approvalN/A
2022-12-21 18:35 ESTNewsHow Well Does Anavex's New Alzheimer's Drug Compare Against Biogen's New Drug?N/A
2022-12-10 07:25 ESTNewsAnavex: A Thorough Approach To The DataN/A
2022-12-08 04:30 ESTNewsAnavex Life Sciences stock slides as downgraded to neutral at Cantor FitzgeraldN/A
2022-12-06 15:57 ESTNewsAnavex Life Sciences: The Little Company That DidN/A
2022-12-04 07:23 ESTNewsAnavex's Alzheimer's Results Leave Much To Be DesiredN/A
2022-12-02 19:33 ESTNewsAnavex surges 40% as drug improves cognitive function in Alzheimer's patients, meets trial's goalsN/A
2022-12-02 19:32 ESTNewsJones sees Anavex as 'clear M&A target' after Alzheimer's drug's trial successN/A
2022-11-30 14:05 ESTNewsAnavex Life Sciences: Market Unimpressed As Major Alzheimer's Data Readout ArrivesN/A
2022-11-29 21:24 ESTNewsAnavex defended at Cantor on prospects for rare disease therapyN/A
2022-11-29 02:23 ESTNewsAnavex Life Sciences Corp. (AVXL) Q4 2022 Earnings Call TranscriptN/A
2022-11-29 02:23 ESTNewsAnavex drops 16% after fiscal 2022 updateN/A
2022-11-28 08:22 ESTNewsAnavex Life Sciences GAAP EPS of -$0.18 misses by $0.01N/A
2022-11-08 08:37 ESTNewsAnavex Life Sciences At A Pivotal MomentN/A
2022-11-07 15:31 ESTNewsAnavex therapy for Fragile X syndrome gets FDA orphan drug statusN/A
2022-09-29 23:01 ESTNewsBiogen, Eisai cool off after massive run-up following lecanemab Alzheimer's dataN/A
2022-09-21 22:13 ESTNewsAnavex wins new U.S. patent for lead candidateN/A
2022-09-19 19:30 ESTNewsAnavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease DementiaN/A
2022-09-08 07:56 ESTNewsAnavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's DiseaseN/A
2022-08-11 23:27 ESTNewsAnavex And The Debunking Of The Amyloid HypothesisN/A
2022-08-10 12:59 ESTNewsAnavex Life Sciences Corp. (AVXL) CEO Dr. Christopher Missling on Q3 2022 Results - Earnings Call TranscriptN/A
2022-08-09 19:18 ESTNewsAnavex Life Sciences GAAP EPS of -$0.16 beats by $0.01N/A
2022-08-08 20:39 ESTNewsAnavex Life Sciences Q3 2022 Earnings PreviewN/A
2022-08-01 22:33 ESTNewsAnavex gains on the effect of Alzheimer’s drug on genesN/A
2022-06-24 04:00 ESTNewsAnavex gains as Berenberg launches coverage with Buy ratingN/A
2022-06-02 22:17 ESTNewsAnavex's Blarcamesine: Why It May Treat Alzheimer's DiseaseN/A
2022-05-31 18:54 ESTNewsAnavex: Increasing Shareholder Value Against All OddsN/A
2022-05-11 00:41 ESTNewsAnavex Life Sciences GAAP EPS of -$0.14 beats by $0.03N/A
2022-05-11 00:40 ESTNewsAnavex Life Sciences GAAP EPS of -$0.14 beats by $0.05N/A
2022-05-11 00:40 ESTNewsAnavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q2 2022 Results - Earnings Call TranscriptN/A
2022-05-10 02:36 ESTNewsAnavex Life Sciences Q2 2022 Earnings PreviewN/A
2022-03-24 04:50 ESTNewsAnavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's DiseaseN/A
2022-03-15 17:38 ESTNewsAnavex posts mid-stage biomarker data for lead candidateN/A

About Anavex Life Sciences Corp (AVXL):

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.

AVXL Quotes by TradingView

See Advanced Chart

General

  • Name Anavex Life Sciences Corp
  • Symbol AVXL
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 20
  • Last Split Factor1:4
  • Last Split Date2015-10-07
  • Fiscal Year EndSeptember
  • IPO Date2006-08-02
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.anavex.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 23.64
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.50
  • Next Year EPS Estimate -$0.55
  • Next Quarter EPS Estimate -$0.11
  • Return on Assets -41%
  • Return on Equity -76%
  • Earnings Per Share -$0.60
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 1.03 billion
  • Analyst Target Price $15.2
  • Book Value Per Share $0.69
View More

Share Statistics

  • Shares Outstanding 69.49 million
  • Shares Float 67.14 million
  • % Held by Insiders 363%
  • % Held by Institutions 19.19%
  • Shares Short 3.96 million
  • Shares Short Prior Month 4.01 million
  • Short Ratio 0.47
  • Short % of Float 6%
  • Short % of Shares Outstanding 6%
View More

Technicals

  • Beta 0.63
  • 52 Week High $16.39
  • 52 Week Low $2.23
  • 50 Day Moving Average 12.26
  • 200 Day Moving Average 6.92
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Anavex Life Sciences Corp (AVXL) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Anavex Life Sciences Corp (AVXL) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-11$N/A-$0.12-$0.120%
2020-09-302020-12-28$N/A-$0.10-$0.1323.08%
2020-06-302020-08-06$N/A-$0.11-$0.1418.52%
2020-03-312020-05-07$N/A-$0.12-$0.1623.42%
2019-12-312020-02-06$N/A-$0.12-$0.120%
2019-09-302019-12-16$N/A-$0.07-$0.1552.4%
2019-06-302019-08-07$N/A-$0.14-$0.1715.71%
2019-03-312019-05-08$N/A-$0.17-$0.14-21.43%
2018-12-312019-02-07$N/A-$0.16-$0.13-23.08%
2018-09-302018-12-12$N/A-$0.13-$0.11-18.18%
2018-06-302018-08-09$N/A-$0.06-$0.1041.92%
2018-03-312018-05-10$N/A-$0.11-$0.10-10%
2017-12-312018-02-07$N/A-$0.09
2017-09-302017-12-11$N/A-$0.12-$0.10-20%
2017-06-302017-08-07$N/A-$0.09-$0.091.33%
2017-03-312017-05-10$N/A-$0.04-$0.0955.56%
2016-12-312017-02-07$N/A-$0.08-$0.1127.27%
2016-09-302016-12-12$N/A-$0.18
2016-06-302016-08-11$N/A-$0.06-$0.0924.59%
2016-03-312016-05-11$N/A-$0.06-$0.1660.81%
2015-12-312016-02-08$N/A-$0.12-$0.1414.29%
2015-09-302015-12-29$N/A-$0.21-$0.06-250%
2015-06-302015-08-17$N/A-$0.22
2015-03-312015-05-15$N/A-$0.12
2014-12-312015-02-18$N/A-$0.06
2014-09-302014-12-29$N/A-$0.20-$0.200%
2014-06-302014-08-13$N/A-$0.10
2014-03-312014-05-28$N/A-$0.11
2013-12-312014-02-26$N/A$0.03
2013-09-302013-09-30$N/A-$0.40
2013-06-302013-06-30$N/A-$0.02
2013-03-312013-03-31$N/A-$0.01
2012-12-312012-12-31$N/A-$0.06
2012-09-302012-09-30$N/A-$0.10
2012-06-302012-06-30$N/A-$0.64
2012-03-312012-03-31$N/A-$0.13
2011-12-312011-12-31$N/A-$0.33
2011-09-302011-09-30-$0.23
2011-06-302011-06-30$N/A-$0.25
2011-03-312011-03-31-$0.31
2010-12-312010-12-31-$0.31
2010-09-302010-09-30-$0.52
2010-06-302010-06-30-$0.37
2010-03-312010-03-31-$0.33
2009-12-312009-12-31-$0.09
2009-09-302009-09-30-$0.36
2009-06-302009-06-30-$0.27
2009-03-312009-03-31-$0.25
2008-12-312008-12-31-$0.19
2008-09-302008-09-30-$0.42
2008-06-302008-06-30-$0.34
2008-03-312008-03-31-$0.14
2007-12-312007-12-31-$0.19
2007-09-302007-09-30-$0.24
2007-06-302007-06-30-$0.05
2007-03-312007-03-31-$0.04
2006-12-312006-12-31$-0.00
2006-09-302006-09-30$-0.00

Anavex Life Sciences Corp (AVXL) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Anavex Life Sciences Corp (AVXL) Chart:

Anavex Life Sciences Corp (AVXL) News:

Below you will find a list of latest news for Anavex Life Sciences Corp (AVXL) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Anavex Life Sciences Corp (AVXL) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-06-2010CALL0 00TRUE00
2025-06-2020CALL0 0466.96TRUE00
2025-06-2030CALL0 0226TRUE00
2025-06-2040CALL0 1245.21TRUE00
2025-06-2052.8CALL1 1108.6TRUE2.80
2025-06-2060CALL0 2297.97TRUE00
2025-06-2070.9CALL0 18160.24TRUE00
2025-06-2080.31CALL8 92563.51FALSE0.010.03
2025-06-2090.14CALL5 121380.2FALSE0.091.8
2025-06-20100.05CALL0 34873.15FALSE00
2025-06-20110.03CALL0 189108.08FALSE00
2025-06-20120.1CALL0 131112.71FALSE00
2025-06-20130CALL0 198145.82FALSE00
2025-06-20140CALL0 470161.72FALSE00
2025-06-20150CALL0 0250.57FALSE00
2025-06-20160CALL0 0266.49FALSE00
2025-06-20170CALL0 67281.09FALSE00
2025-06-2010PUT0 0895.93FALSE00
2025-06-2020PUT0 0577.6FALSE00
2025-06-2030PUT0 0417.45FALSE00
2025-06-2040PUT0 0309.48FALSE00
2025-06-2050PUT0 18158.05FALSE00
2025-06-2060.1PUT0 16880.03FALSE00
2025-06-2070.13PUT11 16568.73FALSE0.130
2025-06-2080.59PUT71 42675.2TRUE0.590
2025-06-2091.51PUT0 2654.21TRUE00
2025-06-20102.25PUT5 681.36TRUE2.250
2025-06-20110PUT0 0177.17TRUE00
2025-06-20120PUT0 0224.5TRUE00
2025-06-20130PUT0 0268.47TRUE00
2025-06-20140PUT0 0245.44TRUE00
2025-06-20150PUT0 0329.25TRUE00
2025-06-20160PUT0 0234.95TRUE00
2025-06-20170PUT0 0198.71TRUE00
2025-07-1810CALL0 00TRUE00
2025-07-1820CALL0 0272.53TRUE00
2025-07-1830CALL0 0168.39TRUE00
2025-07-1840CALL0 0195.25TRUE00
2025-07-1852.65CALL0 46123.45TRUE00
2025-07-1860CALL0 6779.79TRUE00
2025-07-1871.24CALL20 10075.97TRUE1.240
2025-07-1880.74CALL10 42176.93FALSE0.740
2025-07-1890.47CALL6 61182.73FALSE0.020.04
2025-07-18100.31CALL21 341088.07FALSE0.310
2025-07-18110.2CALL0 54898.09FALSE00
2025-07-18120.1CALL0 531101.41FALSE00
2025-07-18130.15CALL0 135183.13FALSE00
2025-07-18140.05CALL0 429158.24FALSE00
2025-07-18150CALL0 661151.43FALSE00
2025-07-18160CALL0 506156.92FALSE00
2025-07-18170CALL0 1058165.55FALSE00
2025-07-18180CALL0 25164.46FALSE00
2025-07-18200CALL0 1491192.2FALSE00
2025-07-18250.1CALL0 217162.04FALSE00
2025-07-1810PUT0 25378.48FALSE00
2025-07-1820PUT0 0392.76FALSE00
2025-07-1830PUT0 276247.24FALSE00
2025-07-1840PUT0 244170.84FALSE00
2025-07-1850.15PUT0 240119.19FALSE00
2025-07-1860.2PUT0 417100.92FALSE00
2025-07-1870.33PUT0 43081.31FALSE00
2025-07-1880.96PUT75 49480.44TRUE0.030.03
2025-07-1891.92PUT0 347116.65TRUE00
2025-07-18102.4PUT5 250676.92TRUE2.40
2025-07-18110PUT0 1794.15TRUE00
2025-07-18124.7PUT0 16378.92TRUE00
2025-07-18130PUT0 5103.54TRUE00
2025-07-18140PUT0 0100.32TRUE00
2025-07-18150PUT0 0173.8TRUE00
2025-07-18160PUT0 11133.44TRUE00
2025-07-18170PUT0 0163TRUE00
2025-07-18180PUT0 0266.82TRUE00
2025-07-18200PUT0 0203.69TRUE00
2025-07-18250PUT0 0175.55TRUE00
2025-10-1710CALL0 00TRUE00
2025-10-1720CALL0 0204.41TRUE00
2025-10-1730CALL0 0161.92TRUE00
2025-10-1744CALL6 691.1TRUE40
2025-10-1753CALL0 1584.48TRUE00
2025-10-1760CALL0 981.85TRUE00
2025-10-1772.04CALL1 1788.77TRUE2.040
2025-10-1781.61CALL11 3588.55FALSE1.610
2025-10-1791.34CALL1 4392.21FALSE1.340
2025-10-17101.05CALL0 64691.01FALSE00
2025-10-17110.9CALL5 12194.46FALSE0.90
2025-10-17120.89CALL0 111897.14FALSE00
2025-10-17130CALL0 5888.51FALSE00
2025-10-17140CALL0 1695.63FALSE00
2025-10-17150.47CALL0 30594.85FALSE00
2025-10-17160.4CALL0 1494.54FALSE00
2025-10-17170CALL0 197.45FALSE00
2025-10-1710PUT0 0354.72FALSE00
2025-10-1720.1PUT0 14195.06FALSE00
2025-10-1730PUT0 67141.35FALSE00
2025-10-1740.35PUT0 15997.97FALSE00
2025-10-1750.55PUT0 4985.37FALSE00
2025-10-1760.8PUT0 296103.15FALSE00
2025-10-1770.93PUT0 3468.99FALSE00
2025-10-1782.15PUT0 20896.03TRUE00
2025-10-1792.6PUT0 22299.74TRUE00
2025-10-17100PUT0 1294.49TRUE00
2025-10-17114PUT0 12101.24TRUE00
2025-10-17120PUT0 977111.66TRUE00
2025-10-17130PUT0 0106.28TRUE00
2025-10-17140PUT0 0108TRUE00
2025-10-17150PUT0 0108.5TRUE00
2025-10-17160PUT0 0111.39TRUE00
2025-10-17170PUT0 0113.46TRUE00
2026-01-1610CALL0 00TRUE00
2026-01-1620CALL0 0134.87TRUE00
2026-01-1634.91CALL523 145474.15TRUE-0.01-0
2026-01-1640CALL0 094TRUE00
2026-01-1653.1CALL0 65883.05TRUE00
2026-01-1660CALL0 086.2TRUE00
2026-01-1672.4CALL0 132986.17TRUE00
2026-01-1681.98CALL0 5782.63FALSE00
2026-01-1691.73CALL2 76086.12FALSE1.730
2026-01-16101.44CALL110 498385.27FALSE1.440
2026-01-16111.25CALL0 2264.38FALSE00
2026-01-16121.15CALL6 334490.27FALSE00
2026-01-16130CALL0 1068.78FALSE00
2026-01-16140CALL0 078.12FALSE00
2026-01-16150.7CALL20 658288.1FALSE-0.06-0.08
2026-01-16160CALL0 083.86FALSE00
2026-01-16170CALL0 7883.83FALSE00
2026-01-16200.5CALL0 6411106.72FALSE00
2026-01-16250.27CALL0 245097.53FALSE00
2026-01-1610PUT0 0275.32FALSE00
2026-01-1620PUT0 0169.76FALSE00
2026-01-1630.2PUT1 1012102.77FALSE0.20
2026-01-1640PUT0 0103.9FALSE00
2026-01-1650.8PUT1 2311100.5FALSE0.80
2026-01-1661.06PUT0 30768.42FALSE00
2026-01-1671.8PUT0 623105.11FALSE00
2026-01-1680PUT0 1598.61TRUE00
2026-01-1693.1PUT1 0100.91TRUE3.10
2026-01-16103.8PUT0 416097.96TRUE00
2026-01-16110PUT0 097.47TRUE00
2026-01-16125.45PUT0 23097.59TRUE00
2026-01-16130PUT0 1096.42TRUE00
2026-01-16140PUT0 098.56TRUE00
2026-01-16157.9PUT0 12090.18TRUE00
2026-01-16160PUT0 0102.89TRUE00
2026-01-16170PUT0 0105.34TRUE00
2026-01-16200PUT0 68101.49TRUE00
2026-01-16250PUT0 1110.85TRUE00
2027-01-1535CALL0 227120.85TRUE00
2027-01-1554.6CALL0 11838.5TRUE00
2027-01-1573.5CALL0 46469.43TRUE00
2027-01-15102.65CALL37 150381.57FALSE-0.05-0.02
2027-01-15122.36CALL4 22084.51FALSE2.360
2027-01-15151.95CALL0 50793.3FALSE00
2027-01-15170CALL0 23594.86FALSE00
2027-01-15201.4CALL0 128678.85FALSE00
2027-01-1530PUT0 2104.06FALSE00
2027-01-1550PUT0 34109.23FALSE00
2027-01-1572.53PUT0 2564.25FALSE00
2027-01-15105.05PUT0 83102.25TRUE00
2027-01-15120PUT0 078.19TRUE00
2027-01-15150PUT0 080.35TRUE00
2027-01-15170PUT0 282.37TRUE00
2027-01-152013.85PUT0 279.64TRUE00

Latest AVXL Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST200$7.57
Jun 13, 2022 7:59 PM EST58$7.56
Jun 13, 2022 7:59 PM EST1$7.57
Jun 13, 2022 7:59 PM EST100$7.57
Jun 13, 2022 7:59 PM EST29$7.56

Anavex Life Sciences Corp (AVXL) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000712/0001731122-20-000712-index.htm
2017-06-09UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1314052/000000000017020197/0000000000-17-020197-index.htm
2019-07-11UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1314052/000000000019011025/0000000000-19-011025-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000083423720008231/0000834237-20-008231-index.htm
2020-03-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000083423720009195/0000834237-20-009195-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000090571818000242/0000905718-18-000242-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000090571819000231/0000905718-19-000231-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000090571820000234/0000905718-20-000234-index.htm
2019-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000121390019010249/0001213900-19-010249-index.htm
2019-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000121390019010601/0001213900-19-010601-index.htm
2019-06-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000121390019010604/0001213900-19-010604-index.htm
2019-07-03S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1314052/000121390019012072/0001213900-19-012072-index.htm
2019-07-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1314052/000121390019012578/0001213900-19-012578-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000121390019014791/0001213900-19-014791-index.htm
2019-09-13S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1314052/000121390019018007/0001213900-19-018007-index.htm
2019-09-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000121390019018012/0001213900-19-018012-index.htm
2019-09-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000121390019018023/0001213900-19-018023-index.htm
2019-09-16AWAmendment Withdrawal Requesthttps://www.sec.gov/Archives/edgar/data/1314052/000121390019018132/0001213900-19-018132-index.htm
2019-09-17POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1314052/000121390019018310/0001213900-19-018310-index.htm
2017-06-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1314052/000161577417003075/0001615774-17-003075-index.htm
2017-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577417004118/0001615774-17-004118-index.htm
2017-08-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004281/0001615774-17-004281-index.htm
2017-08-11S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004290/0001615774-17-004290-index.htm
2017-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004399/0001615774-17-004399-index.htm
2017-08-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004574/0001615774-17-004574-index.htm
2017-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004587/0001615774-17-004587-index.htm
2017-08-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004745/0001615774-17-004745-index.htm
2017-08-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004809/0001615774-17-004809-index.htm
2017-08-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004886/0001615774-17-004886-index.htm
2017-09-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004918/0001615774-17-004918-index.htm
2017-09-07424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1314052/000161577417004964/0001615774-17-004964-index.htm
2017-09-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004994/0001615774-17-004994-index.htm
2017-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005014/0001615774-17-005014-index.htm
2017-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005088/0001615774-17-005088-index.htm
2017-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005183/0001615774-17-005183-index.htm
2017-09-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005226/0001615774-17-005226-index.htm
2017-09-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005351/0001615774-17-005351-index.htm
2017-09-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005440/0001615774-17-005440-index.htm
2017-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005508/0001615774-17-005508-index.htm
2017-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005604/0001615774-17-005604-index.htm
2017-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005634/0001615774-17-005634-index.htm
2017-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005731/0001615774-17-005731-index.htm
2017-10-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005767/0001615774-17-005767-index.htm
2017-10-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005807/0001615774-17-005807-index.htm
2017-10-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005861/0001615774-17-005861-index.htm
2017-10-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005929/0001615774-17-005929-index.htm
2017-12-1110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1314052/000161577417007272/0001615774-17-007272-index.htm
2017-12-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417007355/0001615774-17-007355-index.htm
2017-12-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417007357/0001615774-17-007357-index.htm
2018-02-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577418000934/0001615774-18-000934-index.htm
2018-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001587/0001615774-18-001587-index.htm
2018-03-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001629/0001615774-18-001629-index.htm
2018-03-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001650/0001615774-18-001650-index.htm
2018-03-08DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001673/0001615774-18-001673-index.htm
2018-03-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001701/0001615774-18-001701-index.htm
2018-03-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001744/0001615774-18-001744-index.htm
2018-04-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577418002786/0001615774-18-002786-index.htm
2018-04-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418002846/0001615774-18-002846-index.htm
2018-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577418003574/0001615774-18-003574-index.htm
2018-05-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418004019/0001615774-18-004019-index.htm
2018-05-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418004023/0001615774-18-004023-index.htm
2018-07-06424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000161577418006278/0001615774-18-006278-index.htm
2018-07-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577418006280/0001615774-18-006280-index.htm
2018-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577418007805/0001615774-18-007805-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010436/0001615774-18-010436-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010439/0001615774-18-010439-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010441/0001615774-18-010441-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010443/0001615774-18-010443-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010445/0001615774-18-010445-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010447/0001615774-18-010447-index.htm
2018-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010620/0001615774-18-010620-index.htm
2018-12-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1314052/000161577418014328/0001615774-18-014328-index.htm
2019-01-2510-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1314052/000161577419001031/0001615774-19-001031-index.htm
2019-01-31PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1314052/000161577419001498/0001615774-19-001498-index.htm
2019-02-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577419002057/0001615774-19-002057-index.htm
2019-02-11DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314052/000161577419002242/0001615774-19-002242-index.htm
2019-03-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000161577419004136/0001615774-19-004136-index.htm
2019-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577419004139/0001615774-19-004139-index.htm
2019-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577419005452/0001615774-19-005452-index.htm
2019-05-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577419007213/0001615774-19-007213-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/0001615774-19-007324-index.htm
2019-12-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1314052/000173112219000784/0001731122-19-000784-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000018/0001731122-20-000018-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000019/0001731122-20-000019-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000020/0001731122-20-000020-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000021/0001731122-20-000021-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000022/0001731122-20-000022-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000023/0001731122-20-000023-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000024/0001731122-20-000024-index.htm
2020-02-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000103/0001731122-20-000103-index.htm
2020-02-20DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000195/0001731122-20-000195-index.htm
2020-03-23DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000289/0001731122-20-000289-index.htm
2020-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000360/0001731122-20-000360-index.htm
2020-05-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000430/0001731122-20-000430-index.htm
2020-05-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000431/0001731122-20-000431-index.htm
2020-05-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000432/0001731122-20-000432-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000447/0001731122-20-000447-index.htm
2020-07-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000711/0001731122-20-000711-index.htm
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000712/0001731122-20-000712-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000807/0001731122-20-000807-index.htm
2020-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220001047/0001731122-20-001047-index.htm
2020-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220001114/0001731122-20-001114-index.htm
2017-06-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1314052/999999999517001508/9999999995-17-001508-index.htm
2019-07-15EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1314052/999999999519001606/9999999995-19-001606-index.htm
2019-09-20EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1314052/999999999519002138/9999999995-19-002138-index.htm

Anavex Life Sciences Corp (AVXL) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Anavex Life Sciences Corp (AVXL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 363%
Institutional Ownership: 1919%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2017-08-11CHRISTOPHER U MISSLINGPresident and CEOBuy750.003.552,662.501,004,000.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004281/0001615774-17-004281-index.htm
2017-08-14CHRISTOPHER U MISSLINGPresident and CEOBuy375.003.701,387.501,004,375.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004399/0001615774-17-004399-index.htm
2017-08-18CHRISTOPHER U MISSLINGPresident and CEOBuy375.003.811,428.751,004,750.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004574/0001615774-17-004574-index.htm
2017-08-21CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.071,526.251,005,125.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004587/0001615774-17-004587-index.htm
2017-08-24CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.541,702.501,005,500.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004745/0001615774-17-004745-index.htm
2017-08-28CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.441,665.001,005,875.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004809/0001615774-17-004809-index.htm
2017-08-31CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.481,680.001,006,250.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004886/0001615774-17-004886-index.htm
2017-09-05CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.901,837.501,006,625.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004918/0001615774-17-004918-index.htm
2017-09-07CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.761,785.001,007,000.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004994/0001615774-17-004994-index.htm
2017-09-11CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.811,803.751,007,375.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005014/0001615774-17-005014-index.htm
2017-09-14CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.581,717.501,007,750.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005088/0001615774-17-005088-index.htm
2017-09-18CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.401,650.001,008,125.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005183/0001615774-17-005183-index.htm
2017-09-20CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.231,586.251,008,500.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005226/0001615774-17-005226-index.htm
2017-09-26CHRISTOPHER U MISSLINGPresident and CEOBuy375.003.881,455.001,008,875.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005351/0001615774-17-005351-index.htm
2017-09-28CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.211,578.751,009,250.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005440/0001615774-17-005440-index.htm
2017-10-02CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.201,575.001,009,625.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005508/0001615774-17-005508-index.htm
2017-10-05CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.301,612.501,010,000.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005604/0001615774-17-005604-index.htm
2017-10-13CHRISTOPHER U MISSLINGPresident and CEOBuy750.004.223,165.001,010,750.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005731/0001615774-17-005731-index.htm
2017-10-17CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.271,601.251,011,125.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005767/0001615774-17-005767-index.htm
2017-10-19CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.491,683.751,011,500.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005807/0001615774-17-005807-index.htm
2017-10-24CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.921,845.001,011,875.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005861/0001615774-17-005861-index.htm
2017-10-25CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.391,646.251,012,250.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005929/0001615774-17-005929-index.htm
2018-03-02CHRISTOPHER U MISSLINGDirector, President & CEOBuy1,650.002.413,976.501,013,900.00https://www.sec.gov/Archives/edgar/data/1314052/000161577418001587/0001615774-18-001587-index.htm
2018-03-05CHRISTOPHER U MISSLINGPresident and CEOBuy1,500.002.633,945.001,015,400.00https://www.sec.gov/Archives/edgar/data/1314052/000161577418001629/0001615774-18-001629-index.htm
2018-03-06CHRISTOPHER U MISSLINGPresident and CEOBuy1,450.002.733,958.501,016,850.00https://www.sec.gov/Archives/edgar/data/1314052/000161577418001650/0001615774-18-001650-index.htm
2018-03-07CHRISTOPHER U MISSLINGPresident and CEOBuy1,360.002.923,971.201,018,210.00https://www.sec.gov/Archives/edgar/data/1314052/000161577418001744/0001615774-18-001744-index.htm